Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN TAZOBACTAM versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN TAZOBACTAM versus VEETIDS 500.
Piperacillin-Tazobactam vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category A/B
Category C
Penicillin Antibiotic + Beta-Lactamase Inhibitor
Penicillin Antibiotic